• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    HWH International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    10/25/24 5:00:22 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care
    Get the next $HWH alert in real time by email
    false 0001897245 0001897245 2024-10-21 2024-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 21, 2024

     

    HWH International Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41254   87-3296100

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4800 Montgomery Lane, Suite 210 Bethesda, MD   20814
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (301) 971-3955

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   HWH   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously reported, the Nasdaq Staff (the “Staff”) has notified HWH International Inc. (the “Company”) of certain deficiencies related to the Company’s listing on The Nasdaq Global Market. These deficiencies included the following:

     

    1.On February 22, 2024, the Staff notified the Company that for the previous 30 consecutive trading days, the market value of its publicly held shares (the “MVPHS”) had been below the minimum $15,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(C) (the “Rule”). Therefore, in accordance with Marketplace Rule 5810(c)(3)(D), the Company was provided 180 calendar days, or until August 20, 2024, to regain compliance with the Rule. However, the Company did not regain compliance with the Rule. On August 27, 2024, the Company received a notice from the Staff that the Company would be delisted from The Nasdaq Global Market, unless the Company requested a hearing before a Nasdaq Hearings Panel (the “Panel”). The Company filed the hearing request.
       
    2.On March 7, 2024, we received notice from Nasdaq indicating that, because the market value of our common stock had been below $50,000,000 for the prior 37 consecutive business days, we no longer complied with the minimum market value of listed securities (the “MVLS”) requirement for continued listing on the Nasdaq Global Market under Rule 5450(b)(2)(A) of the Nasdaq Listing Rules. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(C), we were provided an initial compliance period of 180 calendar days, or until September 3, 2024, to regain compliance with the MVLS requirement. The Company did not regain compliance. On September 9, 2024, the Company received a notice from the Staff that the matter of the MVLS deficiency would be considered at the Company’s hearing with the Panel.

     

    Notwithstanding the foregoing, the Company presented its compliance plan to the Panel at a hearing on October 15, 2024. On October 21, 2024, the Company received a notice from the Panel granting the Company an extension to phase down its securities to The Nasdaq Capital Market and demonstrate compliance with the MVPHS and Stockholders’ Equity requirements as set forth in Nasdaq Listing Rules 5550(a)(5) and 5550(b)(1). The Company is working to complete the steps in its compliance plan and regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market within the Panel’s extension.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 25, 2024 HWH INTERNATIONAL INC.
         
      By: /s/ Rongguo Wei                      
      Name:  Rongguo Wei
      Title: Chief Financial Officer

     

     

     

     

    Get the next $HWH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HWH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HWH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by HWH International Inc.

    SCHEDULE 13D/A - HWH International Inc. (0001897245) (Subject)

    4/1/26 9:00:01 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form 10-K filed by HWH International Inc.

    10-K - HWH International Inc. (0001897245) (Filer)

    3/25/26 7:02:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form DEFM14C filed by HWH International Inc.

    DEFM14C - HWH International Inc. (0001897245) (Filer)

    2/17/26 9:00:21 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Issuer)

    4/1/26 9:00:02 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Reporting)

    3/24/26 4:05:21 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Large owner Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Reporting)

    1/20/26 4:59:26 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chan Heng Fai Ambrose bought $585,000 worth of shares (1,300,000 units at $0.45) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    12/26/24 5:15:05 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Director Chan Heng Fai Ambrose bought $3,000,000 worth of shares (4,411,764 units at $0.68) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    11/26/24 7:12:12 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Chan Heng Fai Ambrose bought $3,801,758 worth of shares (6,034,537 units at $0.63) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    9/26/24 9:39:51 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HWH International Inc. Announces Reverse Stock Split

    BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced a 1-for-5 reverse stock split of the Company's common stock to become effective at 9:00 a.m. (Eastern Time) on February 24, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on February 24, 2025, under the existing trading symbol "HWH." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 448

    2/20/25 8:50:00 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

    BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,900, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,412,500 shares of common stock and 1,000,000 pre-funded warrants to purchase 1,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded

    1/7/25 11:18:56 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share

    BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,875, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,125,000 shares of common stock and 1,250,000 pre-funded warrants to purchase 1,250,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded w

    1/6/25 4:20:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/26/24 7:34:11 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/22/24 5:00:10 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by HWH International Inc.

    SC 13G/A - HWH International Inc. (0001897245) (Subject)

    11/14/24 12:40:52 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Financials

    Live finance-specific insights

    View All

    HWH International Inc. Acquires Café in South Korea, Unveiling Second Hapi Cafe Outlet

    Bethesda, MD, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. ("HWH") (NASDAQ:HWH) proudly announces the acquisition of a café in Seocho-gu, South Korea, marking the launch of its second Hapi Cafe outlet in South Korea. HWH is delighted to reveal its latest acquisition of a café nestled in the heart of Seocho-gu, South Korea. This strategic move signifies HWH's dedication to providing unique and welcoming spaces where people can gather to savor food, coffee, and experiences. These cafes are a significant driver of our Health, Wealth, and Happiness vision to offer delicious and nutritious food and beverages to our customers and provide a platform where we can roll out lifestyle pr

    2/26/24 4:15:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care